These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34907641)

  • 1. Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma.
    Kang E; Martinez M; Moisander-Joyce H; Saenger YM; Griesemer AD; Kato T; Yamashiro DJ; Remotti H; Gartrell RD
    Pediatr Transplant; 2022 May; 26(3):e14209. PubMed ID: 34907641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss.
    Wang T; Chen Z; Liu Y; Jia Y; Ju W; Chen M; Zhao Q; Wang D; Guo Z; Tang Y; He X
    Liver Transpl; 2023 Jun; 29(6):598-606. PubMed ID: 36747346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
    Qiu J; Tang W; Du C
    Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab.
    Kuo FC; Chen CY; Lin NC; Liu C; Hsia CY; Loong CC
    Transplant Proc; 2023 May; 55(4):878-883. PubMed ID: 37127513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
    Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
    Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy.
    Dehghan Y; Schnickel GT; Hosseini M; Burgoyne AM; Ajmera VH; Morris GP; Mendler MH; Parekh JR; Abushamat F; Vodkin I; Kono Y
    Clin J Gastroenterol; 2021 Dec; 14(6):1718-1724. PubMed ID: 34643885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Effects of Anti-PD1 Immunotherapy on Hepatocellular Carcinoma Under Administration of Tacrolimus.
    Hsu YC; Chen CH; Huang HF; Lee YT; Wu MC; Su CW; Chou HC; Wang LF; Lee HS; Lin SW; Hsu PN; Wu YM; Sheu JC; Weng MT
    Transplantation; 2023 Jul; 107(7):1492-1501. PubMed ID: 36380450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.
    Su CW; Hou MM; Huang PW; Chou YC; Huang BS; Tseng JH; Hsu CW; Chang TC; Lin SM; Lin CC
    Am J Cancer Res; 2022; 12(4):1606-1620. PubMed ID: 35530291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
    Pfister D; Núñez NG; Pinyol R; Govaere O; Pinter M; Szydlowska M; Gupta R; Qiu M; Deczkowska A; Weiner A; Müller F; Sinha A; Friebel E; Engleitner T; Lenggenhager D; Moncsek A; Heide D; Stirm K; Kosla J; Kotsiliti E; Leone V; Dudek M; Yousuf S; Inverso D; Singh I; Teijeiro A; Castet F; Montironi C; Haber PK; Tiniakos D; Bedossa P; Cockell S; Younes R; Vacca M; Marra F; Schattenberg JM; Allison M; Bugianesi E; Ratziu V; Pressiani T; D'Alessio A; Personeni N; Rimassa L; Daly AK; Scheiner B; Pomej K; Kirstein MM; Vogel A; Peck-Radosavljevic M; Hucke F; Finkelmeier F; Waidmann O; Trojan J; Schulze K; Wege H; Koch S; Weinmann A; Bueter M; Rössler F; Siebenhüner A; De Dosso S; Mallm JP; Umansky V; Jugold M; Luedde T; Schietinger A; Schirmacher P; Emu B; Augustin HG; Billeter A; Müller-Stich B; Kikuchi H; Duda DG; Kütting F; Waldschmidt DT; Ebert MP; Rahbari N; Mei HE; Schulz AR; Ringelhan M; Malek N; Spahn S; Bitzer M; Ruiz de Galarreta M; Lujambio A; Dufour JF; Marron TU; Kaseb A; Kudo M; Huang YH; Djouder N; Wolter K; Zender L; Marche PN; Decaens T; Pinato DJ; Rad R; Mertens JC; Weber A; Unger K; Meissner F; Roth S; Jilkova ZM; Claassen M; Anstee QM; Amit I; Knolle P; Becher B; Llovet JM; Heikenwalder M
    Nature; 2021 Apr; 592(7854):450-456. PubMed ID: 33762733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period.
    Chen GH; Wang GB; Huang F; Qin R; Yu XJ; Wu RL; Hou LJ; Ye ZH; Zhang XH; Zhao HC
    Transpl Immunol; 2021 Jun; 66():101386. PubMed ID: 33744409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and clinical significance of PD‑1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD‑1 monoclonal antibody.
    Li Z; Li B; Peng D; Xing H; Wang G; Li P; Wang J; Ye G; Chen J
    Int J Oncol; 2018 Jun; 52(6):2079-2092. PubMed ID: 29620156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma.
    Friend BD; Venick RS; McDiarmid SV; Zhou X; Naini B; Wang H; Farmer DG; Busuttil RW; Federman N
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prior to ABOi liver transplant with PD-1 inhibitor in patients with hepatocellular carcinoma: A case report.
    Pan Y; Hu J; Li T; Zhang S; Zhou W; Sun J; Wang J; Li W; Xu J
    Transpl Immunol; 2024 Aug; 85():102079. PubMed ID: 38964516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.
    Rezaee-Zavareh MS; Yeo YH; Wang T; Guo Z; Tabrizian P; Ward SC; Barakat F; Hassanein TI; Dave S; Ajmera V; Bhoori S; Mazzaferro V; Chascsa DMH; Liu MC; Aby ES; Lake JR; Sogbe M; Sangro B; Abdelrahim M; Esmail A; Schmiderer A; Chouik Y; Rudolph M; Sohal D; Giudicelli H; Allaire M; Akce M; Guadagno J; Tow CY; Massoumi H; De Simone P; Kang E; Gartrell RD; Martinez M; Paz-Fumagalli R; Toskich BB; Tran NH; Solino GA; Poltronieri Pacheco DM; Kalman RS; Agopian VG; Mehta N; Parikh ND; Singal AG; Yang JD
    J Hepatol; 2025 Jan; 82(1):107-119. PubMed ID: 38996924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
    Jiang J; Huang H; Chen R; Lin Y; Ling Q
    Front Immunol; 2023; 14():1092401. PubMed ID: 36875077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study.
    Guo Z; Liu Y; Ling Q; Xu L; Wang T; Zhu J; Lin Y; Lu X; Qu W; Zhang F; Zhu Z; Zhang J; Jia Z; Zeng P; Wang W; Sun Q; Luo Q; Hu Z; Zheng Z; Jia Y; Li J; Zheng Y; Wang M; Wang S; Han Z; Yu S; Li C; Zhang S; Xiong J; Deng F; Liu Y; Chen H; Wang Y; Li L; Liang W; Schlegel A; Nashan B; Liu C; Zheng S; He X
    Am J Transplant; 2024 Oct; 24(10):1837-1856. PubMed ID: 38642712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
    Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
    Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
    Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.